Literature DB >> 6506063

Results of surgical treatment of gastric cancer--special reference to pathological findings.

K Yoshida, H Ikeuchi, K Kano, T Machida, M Takahashi, Y Miura, N Miura.   

Abstract

During 16 year period from 1967 to 1982, a total of 1,471 patients with gastric cancer were surgically treated at the authors' clinic and 1,347 of them underwent gastric resection. The 5-year survival rate for 692 of curatively operated patients was 73.8%, in contrast to 11.8% for non-curatively operated cases. A correlation study disclosed the depth of cancer infiltration and the extent of lymphnode metastasis to be most reliable prognostic factors. The 5-year survival rate for stage I cases was 91.0%, 70.0% for stage II, 46.7% for stage III, and 8.6% for stage IV. An improvement in the end-results was attributed mainly to the increased incidence of early cancer in surgical cases, and partially to proper adjuvant chemotherapy for the advanced cancer cases during or long-term after surgery. In fact, the cases of early gastric carcinoma whose depth invasion was limited within the mucosa or submucosa constituted 41.9% of the authors' surgical series in 1967-1982, and 5-year survival rates of patients in stages II, III and IV receiving cancer chemotherapy strikingly improved to 80.6%, 57.3%, and 13.2%, in contrast to 59.7%, 35.2% and 2.4% for control groups not treated with anticancer agents.

Entities:  

Mesh:

Year:  1984        PMID: 6506063     DOI: 10.1620/tjem.144.57

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  2 in total

1.  The significance of preoperative chemotherapy for early gastric carcinoma.

Authors:  K Kumagai; A Yasui; Y Nishida; K Masuo; A Yoshitoshi
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

2.  Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up.

Authors:  J Estape; J J Grau; F Lcobendas; J Curto; M Daniels; N Viñolas; C Pera
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.